Double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: economic evaluation with attention to inpatient and outpatient resource utilization

J Natl Cancer Inst Monogr. 1995:(19):37-40.

Authors

D A Freund¹, R S Dittus

Affiliation

¹ School of Public and Environmental Affairs, Department of Medicine and Family Medicine, Bowen Research Center, Indiana University, Bloomington 47405, USA.

PMID: 7577203

No abstract available

Publication types

Clinical Trial
Controlled Clinical Trial

MeSH terms

Aged
Antineoplastic Agents / therapeutic use*
Cost-Benefit Analysis
Cytarabine / administration & dosage
Daunorubicin / administration & dosage
Double-Blind Method
Granulocyte Colony-Stimulating Factor / administration & dosage*
Humans
Leukemia, Myeloid, Acute / drug therapy*
Middle Aged
Outpatients
Randomized Controlled Trials as Topic / economics*
Recombinant Proteins / administration & dosage

Substances

Antineoplastic Agents
Recombinant Proteins
Cytarabine
Granulocyte Colony-Stimulating Factor
Daunorubicin